posted June 29, 2017
The CRNBC board on June 16, 2017, approved new nurse practitioner standards, limits and conditions that set out the requirements for both induction (initiation) and continuation/maintenance prescribing of opioid agonist treatment for opioid use disorder. It's important to note these standards, limits and conditions are
not yet in effect.
In the interim, NPs are able to begin the education and preceptorship process for opioid agonist treatment prescribing via the BC Centre on Substance Use as soon as it becomes available. Contact the BC Centre on Substance Use (bccsu.ca) for more information.
Nurse practitioners who currently prescribe or who desire to prescribe buprenorphine-naloxone on a continuation basis may do so according to the standards, limits and conditions set out in
Part 2, Section D of the NP Scope of Practice document. When the new standards for opioid agonist treatment prescribing come into effect, the existing standards, limits and conditions for continuation prescribing of buprenorphine-naloxone will be rescinded.
Opioid agonist drugs used for the treatment of opioid use disorder are controlled drugs under the
Controlled Drugs and Substances Act. The
Narcotic Control Regulations require methadone prescribers to hold an exemption from Health Canada under section 56 of the Controlled Drugs and Substances Act.
Before prescribing opioid agonist treatment for opioid use disorder, NPs will need to have completed the requirements for Controlled Drugs and Substances prescribing as set out in the
Part 2, Section C of the Scope of Practice for NPs document.
The new standards, limits and conditions will come into effect when the following is in place:
CRNBC is working with external stakeholders to develop and implement these processes. We will notify you when the new standards come into effect via the NP newsletter.